China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...

Use of the GLP-1 agonist was associated, however, with an increased risk of side effects, particularly gastrointestinal symptoms such as nausea, which occurred in nearly half of patients.

Adolescents and young adults are increasingly using GLP-1 receptor agonists for weight management, raising concerns among ...

Liraglutide, a medication commonly used to treat diabetes, has shown promising results in reducing chronic migraine in ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...